TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15670788

Group type: EXPERIMENTAL
Intervention: Haplotype V3‐V4 (G‐C)
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: S100B gene
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: S100B serum concentration
Number of subjects: 785
Study: 12765846

Group type: EXPERIMENTAL
Intervention: n‐3 fatty acid supplementation (3.6g n‐3 fatty acids/day containing 2.4 g of EPA and DHA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo capsules containing olive oil
Number of subjects: 150
Study: 10580781

Group type: EXPERIMENTAL
Intervention: Active treatment groups (hormone therapy)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 5
Study: 7562389

Group type: EXPERIMENTAL
Intervention: Inference-instructed group
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Stimuli from different sources
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Incidental association with stimulus behavior
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Explicit trait inferences after several days
Number of subjects: 5
Study: 2366533

Group type: EXPERIMENTAL
Intervention: 15 min exercise at VO2 20% below VT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 30 min exercise at VO2 20% below VT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 45 min exercise at VO2 20% below VT
Number of subjects: 22
Study: 39387

Group type: EXPERIMENTAL
Intervention: Talinolol (Cordanum)
Number of subjects: 224
Study: 31312252

Group type: EXPERIMENTAL
Intervention: Cox regression with linear interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariable Fractional Polynomials for Interaction (MFPI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local Partial-Likelihood Bootstrap (LPLB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Categorization of continuous covariates (splitting at the median, quartiles, or optimal split)
Number of subjects: 0
Study: 27817246

Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Strength followed by endurance training (ST-END)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endurance followed by strength training (END-ST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No training (CON)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All training interventions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Strength training (ST) and Endurance followed by strength training (END-ST)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endurance followed by strength training (END-ST) and Strength training (ST)
Number of subjects: 30
Study: 26232241

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400mg (AOM 400)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Paliperidone palmitate once-monthly (PP)
Number of subjects: 295
Study: 22415652

Group type: EXPERIMENTAL
Intervention: Self-expandable metallic stents (SEMSs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plastic tube stents (PSs)
Number of subjects: 60
Study: 22010090

Group type: EXPERIMENTAL
Intervention: Magnesium-enriched hydroxyapatite (MHA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Porcine bone (PB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (unfilled sockets)
Number of subjects: 15
Study: 20014653

Group type: COMPARATOR
Intervention: Diffusion Tensor Imaging (DTI) in D/P-PALS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Diffusion Tensor Imaging (DTI) in P/S-PALS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Apparent Diffusion Coefficient (avADC) in D/P-PALS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Apparent Diffusion Coefficient (avADC) in P/S-PALS
Number of subjects: 32

Group type: COMPARATOR
Intervention: N-acetylaspartate (NAA)/creatine-phosphocreatine complex (Cr) in D/P-PALS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Choline (Cho)/Cr and myoinositol (mI)/Cr ratios in D/P-PALS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Choline (Cho)/Cr and myoinositol (mI)/Cr ratios in P/S-PALS
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: FA values in D/P-PALS with increasing disability
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: avADC values in D/P-PALS with increasing disability
Number of subjects: 32
Study: 17560404

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 14992983

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Guided self-help
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo and guided self-help
Number of subjects: 91
Study: 11208039

Group type: EXPERIMENTAL
Intervention: Individualized dialysate composition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dialysate composition
Number of subjects: 0
Study: 9150318

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d.
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg b.i.d.
Number of subjects: 674

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 674
Study: 8352096

Group type: EXPERIMENTAL
Intervention: Chest radiography
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 35
Study: 3112025

Group type: EXPERIMENTAL
Intervention: Pseudomonas immunoglobulin (250 mg/kg body weight, intravenous route, days 3 to 13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pseudomonas immunoglobulin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no Pseudomonas immunoglobulin)
Number of subjects: 26
Study: 29746282

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sodium valproate 500 mg daily
Number of subjects: 82
Study: 27039242

Group type: EXPERIMENTAL
Intervention: Increase in relative abundance of insulin-like growth factor binding proteins (IGFBPs) and subclasses of apolipoprotein (Apo) and transthyretin
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Increase in relative abundance of 13 proteins predominantly involved in inflammation
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: IGFBP-acid labile subunit, orosomucoid 1 (ORM1), Apo C-I, pyruvate kinase isoenzymes M1/M2
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: 6 proteins involved in inflammation (including ORM1, α-1-antichymotrypsin, reticulocalbin 1, and 3 components of the complement cascade)
Number of subjects: 249
Study: 24683583

Group type: EXPERIMENTAL
Intervention: In situ tissue‐engineered graft containing 54 ± 38 CD34+ cells/mL, rhBMP-2 (1 mg/cm of defect), and crushed cancellous allogeneic bone (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: In situ tissue‐engineered graft containing 1,012 ± 752 CD34+ cells/mL, rhBMP-2 (1 mg/cm of defect), and crushed cancellous allogeneic bone (Group B)
Number of subjects: 40
Study: 23221658

Group type: EXPERIMENTAL
Intervention: Smartphone application training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (handout only)
Number of subjects: 0
Study: 20682875

Group type: EXPERIMENTAL
Intervention: Albendazole (three daily 400-mg doses)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 18646538

Group type: EXPERIMENTAL
Intervention: Intervention group A (health education intervention, two questionnaire surveys before and after intervention)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Intervention group B (health education intervention, one questionnaire survey after intervention)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group C (general hygienic knowledge education, two questionnaire surveys before and after intervention)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Intervention group A
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group C
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Intervention group B
Number of subjects: 270
Study: 15923800

Group type: EXPERIMENTAL
Intervention: Prochlorperazine (15 mg spansules twice daily)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg tablets twice daily)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg tablets twice daily)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Overall group (all treatments)
Number of subjects: 232
Study: 12730546

Group type: EXPERIMENTAL
Intervention: Therapeutic knee tape
Number of subjects: 18

Group type: COMPARATOR
Intervention: Neutral knee tape
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untaped
Number of subjects: 18
Study: 10994404

Group type: EXPERIMENTAL
Intervention: 12 mg adenosine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 18 mg adenosine
Number of subjects: 31
Study: 10323120

Group type: EXPERIMENTAL
Intervention: Topical anesthesia in the anterior mucobuccal fold
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1462581

Group type: EXPERIMENTAL
Intervention: 160 mg propranolol retard in one dose daily for 10 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 25
Study: 6370974

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 30374831

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate and 0.2% sodium hyaluronate treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine digluconate
Number of subjects: 56

Group type: COMPARATOR
Intervention: Neutral solution (placebo)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 56
Study: 30053978

Group type: EXPERIMENTAL
Intervention: Inpatient pulmonary rehabilitation (PR) for 3 weeks
Number of subjects: 383
Study: 27099245

Group type: EXPERIMENTAL
Intervention: Fructose (52 g)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sucrose (65 g)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sucralose (0.1 g)
Number of subjects: 27
Study: 25263326

Group type: EXPERIMENTAL
Intervention: Blueberry treatment (300 g of blueberry) + smoking
Number of subjects: 16

Group type: COMPARATOR
Intervention: Smoking treatment (one cigarette)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control treatment (300 mL of water with sugar) + smoking
Number of subjects: 16
Study: 22215709

Group type: EXPERIMENTAL
Intervention: Purified serum IgG from patients with β2 and/or M3 receptor agonistic activity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Infusion of IgG from patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sequential addition of β‐blocker propranolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sequential addition of NO synthase inhibitor N(G)‐nitro‐L‐arginine methyl ester
Number of subjects: 20
Study: 19464312

Group type: EXPERIMENTAL
Intervention: Frontal and mid-profile pose faces
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Profile view faces
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Half face (one eye visible in frontal and profile view)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mid-frontal faces (both eyes visible)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Upper region of a face
Number of subjects: 3

Group type: COMPARATOR
Intervention: Lower half faces
Number of subjects: 3
Study: 17453366

Group type: EXPERIMENTAL
Intervention: Aerobic exercise regimen (12-week training including guided aerobic exercise once a week and home exercise sessions twice a week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study: 15339760

Group type: EXPERIMENTAL
Intervention: Multimodal pelvic floor rehabilitation (n = 21)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Multimodal pelvic floor rehabilitation with abdominal muscle training (n = 23)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control non-pelvic floor rehabilitation (n = 20)
Number of subjects: 64
Study: 11676232

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Partial fundoplication
Number of subjects: 103

Group type: COMPARATOR
Intervention: Laparoscopic group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Various surgical techniques (simple closure of His angle, Hill operation, Belsey Mark IV technique, Angelchik prosthesis)
Number of subjects: 103
Study: 9739036

Group type: EXPERIMENTAL
Intervention: Daily oral food supplements for 4 weeks in addition to hospital food
Number of subjects: 42

Group type: COMPARATOR
Intervention: Only hospital food for 4 weeks
Number of subjects: 42
Study: 8037025

Group type: EXPERIMENTAL
Intervention: Signal averaging
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phase reordering
Number of subjects: 30
Study: 3196076

Group type: EXPERIMENTAL
Intervention: metaproterenol sulfate in aerosolized saline solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo (aerosolized saline only)
Number of subjects: 20

Group type: COMPARATOR
Intervention: no pretreatment
Number of subjects: 20
Study: 29294357

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.17%
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 54
Study: 27417199

Group type: EXPERIMENTAL
Intervention: Crew resource management team training intervention with SBAR tool for structured communication during patient referrals.
Number of subjects: 0
Study: 26634203

Group type: EXPERIMENTAL
Intervention: Tailored anterior transvaginal mesh surgery (ATVM)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Tailored posterior transvaginal mesh surgery (PTVM)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Urodynamic studies
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Quality of life improvement
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 104
Study: 23394141

Group type: EXPERIMENTAL
Intervention: Increased maternal and infant intake of n-3 PUFAs and oily fish, reduced parental smoking, and reduced indoor dampness during pregnancy and the children's first 2 years of life.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cohort (not specified in detail).
Number of subjects: 0
Study: 21084796

Group type: EXPERIMENTAL
Intervention: Synaptose Complex KB220Z™
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 18534567

Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 12
Study: 15997963

Group type: EXPERIMENTAL
Intervention: Hemarcol together with Vitremer
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cavit W
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tricalcium phosphate together with AH26
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Super‐EBA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hemarcol together with Super‐EBA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 90
Study: 12748832

Group type: COMPARATOR
Intervention: Perfusion scintigrams alone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Perfusion scintigrams plus one ventilation image (posterior view)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All perfusion and ventilation images
Number of subjects: 102
Study: 10546188

Group type: EXPERIMENTAL
Intervention: Artemether (3.6 mg/kg on day 1, 1.6 mg/kg for the next 4 days)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Quinine (1.6 mg/kg for the first 4 hours, 8 mg every 8 hours for the next 3 days)
Number of subjects: 84
Study: 8912545

Group type: EXPERIMENTAL
Intervention: Negative estrogen receptor (ER) detection by immunohistochemistry (IHC)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Mib1-positive tumour cells (> 40%)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Initial tumour size less than 4 cm
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: c-erbB-2 overexpression detected by IHC
Number of subjects: 128
Study: 1928529

Group type: EXPERIMENTAL
Intervention: Geriatric assessment unit (GAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 6120706

Group type: EXPERIMENTAL
Intervention: Gel containing fomocaine and diphenhydramine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UV-erythema model
Number of subjects: 16
Study: 31782408

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oxycodone (Oxy)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (I/R)
Number of subjects: 54
Study: 28968224

Group type: EXPERIMENTAL
Intervention: Coaching by retired physicians
Number of subjects: 120

Group type: COMPARATOR
Intervention: No coaching (control group)
Number of subjects: 120
Study: 24732714

Group type: EXPERIMENTAL
Intervention: Hashimoto thyroiditis patients
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 44
Study: 23446109

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 to 40 mg/day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 21062669

Group type: EXPERIMENTAL
Intervention: 2 mg oral estradiol valerate
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 19608684

Group type: EXPERIMENTAL
Intervention: Direct sequencing alone or in combination with denaturing high-performance liquid chromatography
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Allele-specific oligonucleotide polymerase chain reaction techniques
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Allele-specific oligonucleotide polymerase chain reaction
Number of subjects: 200

Group type: COMPARATOR
Intervention: Denaturing high performance liquid chromatography combined with direct sequencing
Number of subjects: 200
Study: 15709655

Group type: EXPERIMENTAL
Intervention: Laser-Doppler perfusion monitoring (LDPM) for measuring post-occlusive reactive hyperemia (PORH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer program developed for fitting the model to measured data
Number of subjects: 0
Study: 12535284

Group type: EXPERIMENTAL
Intervention: Soaps containing betaine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Soaps without betaine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Increasing concentrations of betaine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Non-invasive methods
Number of subjects: 28
Study: 10798801

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) for predicting low risk of lymph node spread (LNS)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) for predicting capsular penetration (CP)
Number of subjects: 409
Study: 8869047

Group type: EXPERIMENTAL
Intervention: AJI software
Number of subjects: 26

Group type: COMPARATOR
Intervention: APIS software
Number of subjects: 26
Study: 1676117

Group type: EXPERIMENTAL
Intervention: Ribavirin (15 mg/kg daily by mouth, average daily dose 1000 mg)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 152

Group type: COMPARATOR
Intervention: Ribavirin and Placebo
Number of subjects: 152
Study: 6219690

Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid (0.5 mg/kg b.w.)
Number of subjects: 76
Study: 29757354

Group type: EXPERIMENTAL
Intervention: Distractor group (operation with a distractor)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (daily exercises)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Distractor group
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 230
Study: 27834736

Group type: EXPERIMENTAL
Intervention: CoDuSe group exercise programme (14 supervised 60-minute sessions over 7 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CoDuSe group exercise programme
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (late start of exercise)
Number of subjects: 48
Study: 25689540

Group type: EXPERIMENTAL
Intervention: Minimum allowable distance policy (500 ft between tobacco outlets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacy and near-schools ban
Number of subjects: 0
Study: 25078976

Group type: EXPERIMENTAL
Intervention: Pregabalin CR (330 mg) administered with food (800-1,000 calorie medium-fat breakfast)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Pregabalin CR (330 mg) administered fasted
Number of subjects: 128

Group type: COMPARATOR
Intervention: Pregabalin IR (300 mg) administered with food
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Pregabalin CR (330 mg) administered with food
Number of subjects: 128

Group type: COMPARATOR
Intervention: Pregabalin IR (300 mg) administered fasted
Number of subjects: 128
Study: 22663901

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for psychosis (CBTp)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 80
Study: 19470889

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 1715

Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg once daily
Number of subjects: 1715

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1715
Study: 17293364

Group type: EXPERIMENTAL
Intervention: MTX + infliximab (IFX)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Subsequent conventional DMARDs (sulfasalazine, leflunomide, hydroxychloroquine, prednisone)
Number of subjects: 244

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 244
Study: 16433247

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (10 nM, 1 M, and 100 M)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 12723391

Group type: EXPERIMENTAL
Intervention: VADO approach
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual rehabilitation practice
Number of subjects: 95
Study: 10389797

Group type: EXPERIMENTAL
Intervention: Chilled 5% albumin (5 mL/kg at 1‐6 degrees C) infused over 5 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chilled 5% albumin (5 mL/kg at 1‐6 degrees C) infused over 30 min
Number of subjects: 0
Study: 8546552

Group type: EXPERIMENTAL
Intervention: Chest radiographs screening
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Normal radiographs
Number of subjects: 1065